- Home
- NXTS
as of 10-23-2026 12:55pm EST
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.
| Founded: | 2009 | Country: | Israel |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 2.1M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 157.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -25.14 | EPS Growth: | -867.42 |
| 52 Week Low/High: | $0.50 - $53.90 | Next Earning Date: | 11-16-2026 |
| Revenue: | $263,445 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -0.02 | Index: | N/A |
| Free Cash Flow: | -3822000.0 | FCF Growth: | N/A |
AI-Powered NXTS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare NXTS vs Leading Stocks
See how NXTS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NXTS Nexentis Technologies Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.